Lessons From Europe: Is It Time for a Regulatory Course Correction?
According to the authors of a paper published in Lancet Oncology, we may have gathered enough evidence to begin to consider altering how these agents are approved, to speed their path to approval.
NOR-SWITCH Shows That Switching Infliximab Biosimilar Is Safe
A study from Norway on whether switching stable patients with rheumatoid arthritis (RA) treated with Remicade® to a biosimilar has revealed that outcomes were no different.
Merck KGaA Seeks to Exit the Biosimilar Business
As a result of increasing competition, a smaller player (in the biosimilar field) is seeking to sell its nascent biosimilar business.
Insulin Glargine Update: Price Savings with Basaglar?
Insulin glargine biosimilars supposed to contribute 15% to total cost savings in overall biologic expenditures.
Last Year's Physician Survey: Barriers to Understanding Biosimilars
Survey shows education will be needed to convince physicians of the value of biosimilar agents.
Amgen's Amjevita at Risk for 2017 Launch
Amgen will await the outcome of its patent litigation with AbbVie before launching Amjevita.
House of Representatives Approves Bipartisan 21st Century Cures Legislation
